In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...
As HPV-vaccinated cohorts age into screening eligibility, researchers evaluated how cervical cancer screening intensity could be tailored by age at vaccination and vaccine type to balance benefits, harms,...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
In an integrated phase 2 analysis of HPV-associated oropharyngeal cancer, FMISO PET-guided chemoradiotherapy de-escalation was associated with 97% 5-year overall survival in both the 30-Gy and 70-Gy...
The FDA approved Enhertu for neoadjuvant treatment of adults with HER2-positive stage II or III breast cancer and adjuvant treatment of patients with residual invasive disease after neoadjuvant therapy.
...
